Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 24, 2026 16:30 ET | Source: Cardiff Oncology, Inc.

Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update

Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs 43.2% with combined SoC of...
February 19, 2026 07:00 ET | Source: Cardiff Oncology, Inc.

Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
January 27, 2026 07:05 ET | Source: Cardiff Oncology, Inc.

Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

- Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in...
January 27, 2026 07:00 ET | Source: Cardiff Oncology, Inc.

Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
December 08, 2025 16:05 ET | Source: Cardiff Oncology, Inc.

Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
December 08, 2025 07:00 ET | Source: Cardiff Oncology, Inc.

Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
November 24, 2025 07:00 ET | Source: Cardiff Oncology, Inc.

Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference

SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
November 06, 2025 16:05 ET | Source: Cardiff Oncology, Inc.

Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update

– Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer – – Expects to...
November 04, 2025 16:01 ET | Source: Cardiff Oncology, Inc.

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
October 02, 2025 16:05 ET | Source: Cardiff Oncology, Inc.

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...